Thymosin beta-4

Drug Profile

Thymosin beta-4

Alternative Names: Fx peptide; GBT-201; RGN-137; RGN-259; RGN-352; RGN-457; TB4; TB4 16-38; Thymosin B4; Thymosin beta 4-16-38; Thymosin beta4; Tβ4

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Chonbuk National University; Defiante Farmaceutica; RegeneRx Biopharmaceuticals; sigma-tau SpA; The George Washington University of Washington, D.C.; United States Army Medical Research Institute of Chemical Defense; Wayne State University; Zhejiang University
  • Class Anti-inflammatories; Peptide hormones; Proteins; Thymus hormones
  • Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Epidermolysis bullosa
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase III Dry eyes; Keratitis
  • Phase II Epidermolysis bullosa
  • Phase I Multiple sclerosis; Myocardial infarction
  • Preclinical Brain injuries; Burns; Diabetic neuropathies; Musculoskeletal disorders; Pulmonary arterial hypertension; Stroke
  • No development reported Eye disorders; Pressure ulcer; Varicose ulcer
  • Discontinued Alopecia; Bronchiectasis; Cystic fibrosis; Diabetic foot ulcer; Diabetic retinopathy; Septic shock

Most Recent Events

  • 01 Mar 2017 Thymosin beta-4 is still in phase II development for epidermolysis bullosa in USA
  • 27 Feb 2017 GtreeBNT plans a phase III trial for Epidermolysis bullosa in USA
  • 10 Jan 2017 RegeneRx Biopharmaceuticals receives a Notice of Acceptance for a patent from the Australian Patent Office for Thymosin beta 4 in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top